Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgrastim - Amgen/Roche

Drug Profile

Filgrastim - Amgen/Roche

Alternative Names: G-CSF; Gracinᵀᴹ; Gran; Granulocyte colony-stimulating factor - Amgen; Granulokine; Grasinᵀᴹ; KRN 8601; Meograstim; Neupogen; Nupen

Latest Information Update: 29 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Apricus Biosciences; Bristol-Myers Squibb; GlaxoSmithKline; Kirin Holdings Company; Kirin-Amgen; Kyowa Hakko Kirin; University of Washington
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage; Neutropenia; Radiation injuries
  • Phase I/II Breast cancer

Most Recent Events

  • 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
  • 08 May 2017 Amgen terminates a phase I/II trial as the sponsor withdrew the study in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT00041470)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top